biostudies-literatureSamanta RJNational Institute for Health Research (NIHR)105310https://www.ebi.ac.uk/biostudies/studies/S-EPMC11424973biostudies-literatureUnknown108<h4>Background</h4>The inflammatory response in patients with traumatic brain injury (TBI) offers opportunities for stratification and intervention. Previous unselected approaches to immunomodulation in patients with TBI have not improved patient outcomes.<h4>Methods</h4>Serum and plasma samples from two prospective, multi-centre observational studies of patients with TBI were used to discover (Collaborative European NeuroTrauma Effectiveness Research [CENTER-TBI], Europe) and validate (Transforming Research and Clinical Knowledge in Traumatic Brain Injury [TRACK-TBI] Pilot, USA) individual variations in the immune response using a multiplex panel of 30 inflammatory mediators. Mediators that were associated with unfavourable outcomes (Glasgow outcome score-extended [GOS-E] ≤ 4) were used fEBioMedicineParsimonious immune-response endotypes and global outcome in patients with traumatic brain injury.PMC11424973NIHR129748Samanta RJFeeser VRRadoi AWilliams GRossi SDuhaime ACGolubovic JZiverte ARossaint RPosti JPGalanaud DCastano-Leon AMValeinis EGopinath SStamatakis ELightfoot RKornaropoulos EVamos ZSmielewski PGrandhi RFoks KCiterio GRhodes JChiollaz ACSummers CZeiler FAGrossi FZafonte RManara AGravesteijn BRodgers RBHaitsma ITamas VMcMahon CDixit ATamosuitis TCarbonara MRocka SYue JKMattern JSakowitz OAndreassen LAmrein KWinzeck SMcCrea MRoise ORosenlund CDepreitere BCENTER-TBI investigators and participantsBlaabjerg MGupta DAudibert GMenovsky TNewcombe VChevallard GBenali HMurray LSandrod OFrederik Schou Rvan Essen TAHelseth ENelson DTudora CMLecky FCzeiter EDella Corte FVulekovic PFurmanov ATakala RTRACK-TBI investigators and participantsĐilvesi ĐHa RJCzosnyka MZanier ERYounsi ARichter SBellander BMLund SBDiaz-Arrastia RDreier JPomposo INeedham EGantner DSanchez-Porras RTolias CBeer RJohnson FZoerle TWolf SMarechal HVajkoczy PPeul WAndelic NRosenfeld JHelbok RPersona PVik AGomez PACalappi EChieregato APuybasset LTibboel Dvan Dijck JTJMDahyot-Fizelier CKowark ACooper JDHelmy AMartino COrtolano FMaas AIRKondziella DSewalt CVolovici VBadjatia NDuliere GLRagauskas AMenon DLaureys SVargiolu ABoogert HDSorinola AManley GTEzer ETrapani TBeretta LCoburn MSDe Keyser VWang KKWKeene DKobeissy FLedoux DVega EThomas MAzouvi PSteyerberg EWStocchetti NCavallo SPayen JFDegos VKoskinen LOCalvi MRBeqiri ECabeleira MAzzolini MLTaylor SRSundstrom NVan der Steen GVallance SMerchant RBerardino MColes JNegru AFrisvold SRoe CUnterberg Avan Wijk RCorreia MMadden CCaccioppola AHutchinson PJWiegers ESchnyer DGhuysen ASchirmer-Mikalsen KGiga LPerlbarg VPiippo-Karjalainen ALozano GCErcole AJankowski SHuijben JBartels RBuki ALagares ATenovuo OSanchez JCNyiradi JVilcinis RKaran MLingsma HFabricius MMisset BRosenthal GDark PPles HClusmann HRaj RKovacs NMenon DKBrorsson CAnke ASahuquillo JAckerlund CNgwenya LBMaas AIKolias AGMuraleedharan VCameron PfalseParsimonious immune-response endotypes and global outcome in patients with traumatic brain injury.<h4>Background</h4>The inflammatory response in patients with traumatic brain injury (TBI) offers opportunities for stratification and intervention. Previous unselected approaches to immunomodulation in patients with TBI have not improved patient outcomes.<h4>Methods</h4>Serum and plasma samples from two prospective, multi-centre observational studies of patients with TBI were used to discover (Collaborative European NeuroTrauma Effectiveness Research [CENTER-TBI], Europe) and validate (Transforming Research and Clinical Knowledge in Traumatic Brain Injury [TRACK-TBI] Pilot, USA) individual variations in the immune response using a multiplex panel of 30 inflammatory mediators. Mediators that were associated with unfavourable outcomes (Glasgow outcome score-extended [GOS-E] ≤ 4) were used f2024-01-01T00:00:00Z2024 Oct2026-06-02T18:42:24.328Z2025-04-04T11:04:16.956ZS-EPMC114249733929321210.1016/j.ebiom.2024.105310